P fgfr1

Samples were homogenized in RIPA buffer (Beyotime Biotechnology) with protease and phosphatase Inhibitor (Thermo Fisher). Western blot analyses were carried out in accordance with standard protocols, and membranes were incubated with anti-FGF2 (1:200, Proteintech), anti-GPR30 (1:100, Abcam), phospho-Mek (1:1000, Cell Signaling Technology), Mek (1:1000, Cell Signaling Technology), phospho-p44/42 MAPK (p-Erk1/2, 1:1000, Cell Signaling Technology), p44/42 MAPK (Erk1/2, 1:1000, Cell Signaling Technology), p-FGFR1 (1:500, Abcam), and GAPDH (1:5000, Proteintech). The membranes were incubated with HRP-conjugated antibodies goat anti-rabbit (1:10000, Abcam) or goat anti-mouse (1:10000, Abcam). They were imaged on the Image Quant LAS 4000 mini biomolecular imager (GE Healthcare Life Sciences) after being applied with EZ-ECL (Biological Industries). The relative protein levels were measured by Image J software (National Institutes of Health) and normalized over the expression of GAPDH.

Antibodies against FN (Cat#15613-1-AP), COL1A1 (Cat#67288-1-lg), α-SMA (Cat#55135-1-AP, Cat#67735-1-AP), FGFR1 (Cat#60325-1-lg), CD31 (Cat#60287-1-lg), CD45 (Cat#11265-1-lg), EpCAM (Cat#60287-1-lg), Vimentin (Cat#10366-1-AP) and GAPDH (Cat#60004-1-lg) were purchased from Proteintech (Rosemont, IL, USA). Antibodies against p-EGFR (Cat#3777S), EGFR (Cat#4267), p-VEGFR2 (Cat#2478), VEGFR2 (Cat#9698), PDGFRβ (Cat#3169), p-PLCγ1 (Cat#2821), PLCγ1 (Cat#5690), p-GAB1 (Cat#12745), GAB1 (Cat#3232), p-SHC (Cat#2434), SHC (Cat#2432), p-AKT (Cat#4060), AKT (Cat#9272), p-ERK1/2 (Cat#4370), ERK1/2 (Cat#4695), p-STAT3 (Cat#4113), STAT3 (Cat#9139), GRB2 (Cat#3972), GST (Cat#2642) were purchased from Cell Signaling Technology (Danvers, MA, USA). Antibodies against pY (Cat#EPR16871), p-PDGFRβ (Cat#ab248657), p-FGFR1 (Cat#ab59194), α-SMA (Cat#ab124964), pS/pT (Cat#ab117253) and IgG (Cat#EPR25A and Cat#ab37415) were purchased from Abcam (Cambridge, MA, USA). Bleomycin, nintedanib and PHPS1 were purchased from Targetmol (Boston, MA, USA).

Cell count kit‐8 (CCK‐8) was purchased from MedChemExpress. MTT and DMSO were purchased from Sigma. TGF‐β₁ and FGF‐basic were purchased from Novoprotein. PEG 400 was purchased from Sigma. Collagenase Type IV was purchased from GIBCO. Bleomycin sulphate was purchased from Chengdu Synguider Technology Co., Ltd. Nintedanib were purchased from Chengdu Giant Pharmaceutical Technology Co., Ltd (C₃₁H₃₃N₅O₄, MW: 539.62; CAS#656247‐17‐5). Antibodies against p‐Smad2/3 (Cat #8828S) and Smad2/3 (Cat #8685S) were purchased from Cell Signaling Technology. α‐SMA (Cat #ab5694), collagen I (Cat#ab88147), ERK1/2 (Cat #ab32537), FGFR1 (Cat #ab824), p‐FGFR1 (Cat #ab59194), PLCγ (Cat #ab76155), p‐PLCγ (Cat #D25A9) and β‐actin (Cat #ab8226) were purchased from Abcam. GAPDH (Cat #18AF0404, ZSJQ‐BIO). The dilution ratio of all primary antibodies is 1:1000, and the dilution ratio of secondary antibodies is 1:3000.